相似文献
1
Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat.
Br J Pharmacol. 1992 Nov;107(3):750-5. doi: 10.1111/j.1476-5381.1992.tb14518.x.
2
Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.
Br J Pharmacol. 1994 May;112(1):240-9. doi: 10.1111/j.1476-5381.1994.tb13058.x.
3
Identification of the central tachykinin receptor subclass involved in substance P-induced cardiovascular and behavioral responses in conscious rats.
Eur J Pharmacol. 1992 Sep 4;219(3):435-44. doi: 10.1016/0014-2999(92)90485-m.
4
Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.
Br J Pharmacol. 1995 Mar;114(6):1310-6. doi: 10.1111/j.1476-5381.1995.tb13348.x.
5
Intracerebroventricular responses to neuropeptide gamma in the conscious rat: characterization of its receptor with selective antagonists.
Br J Pharmacol. 1996 Jan;117(2):241-9. doi: 10.1111/j.1476-5381.1996.tb15183.x.
6
Characterization of the tachykinin receptors involved in spinal and supraspinal cardiovascular regulation.
Can J Physiol Pharmacol. 1995 Jul;73(7):892-902. doi: 10.1139/y95-123.
7
Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat.
Br J Pharmacol. 1997 Oct;122(4):643-54. doi: 10.1038/sj.bjp.0701435.
8
The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.
Br J Pharmacol. 2005 Jul;145(6):712-27. doi: 10.1038/sj.bjp.0706249.
9
Cardiovascular and behavioural effects of centrally administered neuropeptide K in the rat: receptor characterization.
Br J Pharmacol. 1994 May;112(1):250-6. doi: 10.1111/j.1476-5381.1994.tb13059.x.
10
Role of C-terminal amidation on the biological activity of neurokinin A derivatives with agonist and antagonist properties.
J Pharmacol Exp Ther. 1993 Jan;264(1):17-21.
引用本文的文献
1
The role of neuropeptides in adverse myocardial remodeling and heart failure.
Cell Mol Life Sci. 2017 Jun;74(11):2019-2038. doi: 10.1007/s00018-017-2452-x. Epub 2017 Jan 17.
2
Substance P receptor antagonism: a potential novel treatment option for viral-myocarditis.
Biomed Res Int. 2015;2015:645153. doi: 10.1155/2015/645153. Epub 2015 Mar 2.
3
The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.
Br J Pharmacol. 2005 Jul;145(6):712-27. doi: 10.1038/sj.bjp.0706249.
4
Pituitary adenylate cyclase-activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: Evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene.
Brain Res Mol Brain Res. 2005 Jul 29;138(1):45-57. doi: 10.1016/j.molbrainres.2005.03.016.
5
Behavioral effects of local microinfusion of pituitary adenylate cyclase activating polypeptide (PACAP) into the paraventricular nucleus of the hypothalamus (PVN).
Regul Pept. 2005 May 15;128(1):33-41. doi: 10.1016/j.regpep.2004.12.023.
6
Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat.
Br J Pharmacol. 1999 Jun;127(3):717-28. doi: 10.1038/sj.bjp.0702620.
7
Respiratory action of capsaicin microinjected into the nucleus of the solitary tract: involvement of vanilloid and tachykinin receptors.
Br J Pharmacol. 1999 May;127(2):473-81. doi: 10.1038/sj.bjp.0702522.
8
Intracerebroventricular responses to neuropeptide gamma in the conscious rat: characterization of its receptor with selective antagonists.
Br J Pharmacol. 1996 Jan;117(2):241-9. doi: 10.1111/j.1476-5381.1996.tb15183.x.
9
Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig.
Br J Pharmacol. 1995 Nov;116(5):2496-502. doi: 10.1111/j.1476-5381.1995.tb15101.x.
10
Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.
Br J Pharmacol. 1995 Mar;114(6):1310-6. doi: 10.1111/j.1476-5381.1995.tb13348.x.
本文引用的文献
1
Regional distribution of neuromedin K and neuromedin L in rat brain and spinal cord.
Biochem Biophys Res Commun. 1984 Nov 14;124(3):731-8. doi: 10.1016/0006-291x(84)91019-2.
2
Nucleotide sequences of cloned cDNAs for two types of bovine brain substance P precursor.
Nature. 1983;306(5938):32-6. doi: 10.1038/306032a0.
3
Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing.
Nature. 1984;312(5996):729-34. doi: 10.1038/312729a0.
4
Pharmacologic characterization and autoradiographic distribution of binding sites for iodinated tachykinins in the rat central nervous system.
Peptides. 1986 Nov-Dec;7(6):1109-20. doi: 10.1016/0196-9781(86)90141-5.
5
[3H]neurokinin B and 125I-Bolton Hunter eledoisin label identical tachykinin binding sites in the rat brain.
J Neurochem. 1987 Jan;48(1):125-33. doi: 10.1111/j.1471-4159.1987.tb13136.x.
6
New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization.
Trends Pharmacol Sci. 1988 Aug;9(8):290-5. doi: 10.1016/0165-6147(88)90013-2.
7
Localization of tachykinin binding sites (NK1, NK2, NK3 ligands) in the rat brain.
Peptides. 1988 Mar-Apr;9(2):227-41. doi: 10.1016/0196-9781(88)90255-0.
8
Differential effects of central angiotensin II and substance P on sympathetic nerve activity in conscious rats. Implications for cardiovascular adaptation to behavioral responses.
Circ Res. 1985 Apr;56(4):563-75. doi: 10.1161/01.res.56.4.563.
9
Autoradiographic localization and characterization of tachykinin receptor binding sites in the rat brain and peripheral tissues.
J Neurosci. 1989 Jan;9(1):258-79. doi: 10.1523/JNEUROSCI.09-01-00258.1989.
10
Characterization of the peripheral action of neurokinins and neurokinin receptor selective agonists on the rat cardiovascular system.
Naunyn Schmiedebergs Arch Pharmacol. 1989 Nov;340(5):547-57. doi: 10.1007/BF00260610.
Zotero 插件